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at start of treatment. Patient education and precise individual
dose titration combined with once-daily dosing regimens may
improve persistence with ICS.
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OBJECTIVE: This study models the cost-effectiveness of
tiotropium versus ipratropium in a veterans population while
incorporating information on medication compliance, disease
severity, and history of health care utilization. METHODS: Elec-
tronic medical records from the Veterans Affairs (VA) Maryland
Health Care System for 2004 were analyzed. Inclusion criteria:
1) ﬁlled prescription for ipratropium in 2004; 2) pulmonary
function test (PFT) results; 3) PFT-based evidence of chronic
obstructive pulmonary disease (COPD). Hospitalizations and
emergency room (ER) visits for COPD exacerbations, COPD
severity, and medication adherence were identiﬁed via chart
review. The relative effectiveness of tiotropium was based on
published clinical trial results. The incremental cost-effectiveness
ratio (ICER) was calculated for 702 actual ipratropium patients
and 702 modeled tiotropium patients for two effects: avoided
exacerbations (ICERex) and avoided hospitalizations (ICERhos).
Sensitivity analysis was also conducted. RESULTS: The iprat-
ropium sample characteristics were: mean age of 69 years; 98
percent male; 21 percent Black; and 40 percent smokers. The dis-
tribution by severity was: mild (7%), moderate (42%), severe
(40%) and very severe (11%). The total (exacerbation-related)
ER visits and hospitalizations were 879 (171) and 462 (75),
reﬂecting the exclusion of 40 ER and 9 hospital encounters fol-
lowing missed medications. The overall ICERex and ICERhos
were $1318.38 and $4284.75. Tiotropium was dominant in very
severe patients: ICERex of −$2099.00 and ICERhos of 
−$6297.00. Tiotropium was dominant (−$4215.46) for patients
with one hospitalization and ranged from $433.29 to $117.27
for patients with one to three ER visits. The results were most
sensitive to variation in tiotropium compliance, the cost of ipra-
tropium, and the relative efﬁcacy of tiotropium. CONCLU-
SIONS: Assuming VA efﬁcacy similar to published estimates,
tiotropium is more cost-effective in patients with more severe
disease or a history of ER visits and is dominant when con-
sidering patients with very severe COPD or with a previous 
hospitalization.
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OBJECTIVES: To evaluate the use and costs of all health care
provider services among 1000 patients with chronic asthma
during a ﬁve year period. METHODS: Patients who had visited
the Pulmonary Clinics of Helsinki University Hospital during the
yrs 2000–2004 were invited to the study. The participants’
consent was obtained and a comprehensive medical history col-
lected from all health care providers who had treated the 
participant during the last 5 years. Data included all physician
recorded symptoms, signs, adverse drug effects, complications,
diagnostic test results, given treatments, and procedures as
unstructured text. Using advanced linguistic analysis methods,
we identiﬁed for each event both cost related attributes (loca-
tion, personnel, type of contact, urgency) and clinical attributes
(age, gender, BMI, smoking, lung functions, co-morbidities, and
prescribed medication) potentially explaining the differences
across their clinical outcomes. We developed a medication inde-
pendent score for the stability of asthma based on physician
recorded observations. Membership [0.1] of an asthma related
contact was deﬁned as a probability-like function P. RESULTS:
Our regression model is based on 65,698 health care contacts
explaining a signiﬁcant proportion (43%) of all direct non-
pharmacological costs of the patients. Fifty-six percent of the
contacts were asthma related. An asthma related event occurred
on average 6 times per year with an average cost of €256 (based
on average costs in Finland). Unexpectedly the use of prescrip-
tion antihistamines resulted less frequent patient interaction with
the health care system and potentially in better asthma control.
Smoking, adverse drug events, co-morbidities, existing allergy
symptoms increased asthma related expenditures signiﬁcantly.
Use of antihistamines, normal FVC in spirometry, and male
gender decreased the costs. CONCLUSIONS: This empirical
model of health care utilization can be used to explain differ-
ences in health care utilization among patients with different 
co-morbidities and different treatment protocols.
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OBJECTIVES: Advanced melanoma is usually fatal, with few
effective treatments. Dacarbazine (DTIC) is considered standard
therapy, but newer drugs have recently been marketed. The study
objective was to quantify success rates (Complete + Partial
response) of DTIC alone versus all other comparators in treat-
ing Stage-III (non-resectable) and Stage-IV melanoma of cuta-
neous origin. METHODS: We retrieved all head-to-head
randomized controlled trials involving dacarbazine (DTIC) and
other active drugs or multiple-drug combinations. Two review-
ers searched the literature, and compared results, with differ-
ences resolved through consensus. Success rates were combined
using random effects meta-analysis. Heterogeneity was tested
using chi-square and publication bias using funnel plots and 
the Begg-Mazumdar test. Quality was assessed using Jadad’s
method. RESULTS: We found 23 studies (3356 patients, 1966
DTIC, 1390 other treatments, average age = 52.8 ± 4.3) with
DTIC as standard treatment. Studies were generally of poor
quality; 2 scored “high” quality and 21 scored “low” quality.
Heterogeneity was non-signiﬁcant (chi-square = 24.63, P = 0.32),
suggesting combinability. Funnel plots were not abnormal and
the Begg-Mazumdar test was non-signiﬁcant (tau = −0.13, P =
0.38), indicating no publication bias. DTIC success rate was
14.9%. All other treatments combined were somewhat superior
to DTIC alone (OR = 1.31, CI95%:1.06–1.61). Average survival
time was 7.5 ± 2.0 months for DTIC and 8.7 ± 3.6 months for
all others. Adjunct therapy [DTIC+additional drug(s)] was supe-
